Chevallard Daniel R. — SEC insider filings
SEC reporting owner CIK 1706176. 22 insider filings on record with FilingPulse; latest filed 2026-11-03.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2021-03-30 to 2026-11-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 12,886 shares, $164,280 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 11 legs across 10 filings — 40,231 shares, $99,354 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: purchase of 7,500 shares @ $8.57 ($64,275) in LENZ Therapeutics, Inc., filed 2026-03-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | Chief Financial Officer | 6 | 4 legs · 12,886 sh · $164,280 | — | 4 |
| Viracta Therapeutics, Inc. (VIRX) | CFO and COO | 16 | — | 11 legs · 40,231 sh · $99,354 | 28 |
Insider filings — Chevallard Daniel R.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-03 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 652,063 (derivative) @ $0 | EDGAR |
| 2026-03-30 | 4 | LENZ Therapeutics, Inc. (LENZ) | Purchase (P): 7,500 @ $8.57 | EDGAR |
| 2026-01-06 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | LENZ Therapeutics, Inc. (LENZ) | Purchase (P): 20 @ $22.71 · Purchase (P): 2,178 @ $22.76 | EDGAR |
| 2024-05-15 | 4 | LENZ Therapeutics, Inc. (LENZ) | Purchase (P): 3,188 @ $15.68 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,405 @ $0.73 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2023-11-28 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,720 @ $0.50 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2023-08-29 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,888 @ $0 · Sale (S): 3,512 @ $1.45 · Option exercise (M): 6,888 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,635 @ $1.42 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,599 @ $1.68 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2022-11-29 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,532 @ $2.72 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2022-08-29 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,655 @ $4.02 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2022-05-27 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,596 @ $1.90 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2022-03-18 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2022-03-01 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 6,889 @ $0 · Sale (S): 3,998 @ $2.78 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2021-11-29 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 13,777 @ $0 · Sale (S): 3,254 @ $4.80 · Sale (S): 4,325 @ $4.82 · Option exercise (M): 13,777 (derivative) @ $0 | EDGAR |
| 2021-09-29 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 10,000 @ $0.90 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-01 | 4 | Viracta Therapeutics, Inc. (VIRX) | Option exercise (M): 12,000 @ $0.90 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2021-03-30 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 78,912 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-03-23 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1706176 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs